Skip to main content
. 2017 Jan 27;8(11):17810–17818. doi: 10.18632/oncotarget.14863

Figure 2. Kaplan–Meier survival curves of patients treated with anti-EGFR therapeutics in wild-type groups of KRAS (codon 61/146), NRAS (codon 12/13/61), and BRAF (codon 600).

Figure 2

(A) Progression-free survival according to EZH2 expression in the KRAS wild-type group (N = 102). (B) Progression-free survival according to EZH2 expression in the NRAS wild-type group (N = 101). (C) Progression-free survival according to EZH2 expression in the BRAF wild-type group (N = 103).